Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SHR-1316 + nab-paclitaxel + carboplatin for locally advanced thymic carcinoma
ChiCTR2300074152Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in thymic carcinoma (TC), sponsored by Shanghai Chest Hospital. Primary endpoint: objective response rate. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2300074152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074152.